Go Pro

Arcadia Biosciences (RKDA) Competitors

Arcadia Biosciences logo
$0.46 0.00 (-1.00%)
As of 08/21/2026 04:00 PM Eastern

RKDA vs. KO, PEP, KOF, MNST, and CCEP

Should you buy Arcadia Biosciences stock or one of its competitors? Arcadia Biosciences's main competitors and comparable companies include CocaCola (KO), PepsiCo (PEP), Coca Cola Femsa (KOF), Monster Beverage (MNST), and Coca-Cola Europacific Partners (CCEP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "soft drinks & non-alcoholic beverages" industry.

How does Arcadia Biosciences compare to CocaCola?

Arcadia Biosciences (NASDAQ:RKDA) and CocaCola (NYSE:KO) are both consumer staples companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, dividends, valuation and earnings.

CocaCola has a net margin of 28.56% compared to Arcadia Biosciences' net margin of -234.53%. CocaCola's return on equity of 39.38% beat Arcadia Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Arcadia Biosciences-234.53% -183.50% -91.25%
CocaCola 28.56%39.38%13.18%

17.7% of Arcadia Biosciences shares are held by institutional investors. Comparatively, 70.3% of CocaCola shares are held by institutional investors. 4.5% of Arcadia Biosciences shares are held by company insiders. Comparatively, 0.9% of CocaCola shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Arcadia Biosciences has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market. Comparatively, CocaCola has a beta of 0.33, indicating that its stock price is 67% less volatile than the broader market.

In the previous week, CocaCola had 57 more articles in the media than Arcadia Biosciences. MarketBeat recorded 57 mentions for CocaCola and 0 mentions for Arcadia Biosciences. CocaCola's average media sentiment score of 1.19 beat Arcadia Biosciences' score of 0.00 indicating that CocaCola is being referred to more favorably in the news media.

Company Overall Sentiment
Arcadia Biosciences Neutral
CocaCola Positive

CocaCola has a consensus price target of $95.76, indicating a potential upside of 5.34%. Given CocaCola's stronger consensus rating and higher possible upside, analysts plainly believe CocaCola is more favorable than Arcadia Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arcadia Biosciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
CocaCola
0 Sell rating(s)
3 Hold rating(s)
15 Buy rating(s)
0 Strong Buy rating(s)
2.83

CocaCola has higher revenue and earnings than Arcadia Biosciences. Arcadia Biosciences is trading at a lower price-to-earnings ratio than CocaCola, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arcadia Biosciences$4.86M0.23-$2.34M-$4.56N/A
CocaCola$47.94B8.16$13.11B$3.3327.30

Summary

CocaCola beats Arcadia Biosciences on 14 of the 16 factors compared between the two stocks.

How does Arcadia Biosciences compare to PepsiCo?

Arcadia Biosciences (NASDAQ:RKDA) and PepsiCo (NASDAQ:PEP) are both consumer staples companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, valuation, institutional ownership, media sentiment and earnings.

In the previous week, PepsiCo had 53 more articles in the media than Arcadia Biosciences. MarketBeat recorded 53 mentions for PepsiCo and 0 mentions for Arcadia Biosciences. PepsiCo's average media sentiment score of 1.10 beat Arcadia Biosciences' score of 0.00 indicating that PepsiCo is being referred to more favorably in the news media.

Company Overall Sentiment
Arcadia Biosciences Neutral
PepsiCo Positive

PepsiCo has higher revenue and earnings than Arcadia Biosciences. Arcadia Biosciences is trading at a lower price-to-earnings ratio than PepsiCo, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arcadia Biosciences$4.86M0.23-$2.34M-$4.56N/A
PepsiCo$93.93B2.09$8.24B$7.6318.80

PepsiCo has a net margin of 10.78% compared to Arcadia Biosciences' net margin of -234.53%. PepsiCo's return on equity of 54.63% beat Arcadia Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Arcadia Biosciences-234.53% -183.50% -91.25%
PepsiCo 10.78%54.63%10.49%

Arcadia Biosciences has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market. Comparatively, PepsiCo has a beta of 0.35, suggesting that its share price is 65% less volatile than the broader market.

17.7% of Arcadia Biosciences shares are owned by institutional investors. Comparatively, 73.1% of PepsiCo shares are owned by institutional investors. 4.5% of Arcadia Biosciences shares are owned by company insiders. Comparatively, 0.1% of PepsiCo shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

PepsiCo has a consensus price target of $157.90, suggesting a potential upside of 10.05%. Given PepsiCo's stronger consensus rating and higher possible upside, analysts plainly believe PepsiCo is more favorable than Arcadia Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arcadia Biosciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
PepsiCo
1 Sell rating(s)
12 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.30

Summary

PepsiCo beats Arcadia Biosciences on 14 of the 16 factors compared between the two stocks.

How does Arcadia Biosciences compare to Coca Cola Femsa?

Coca Cola Femsa (NYSE:KOF) and Arcadia Biosciences (NASDAQ:RKDA) are both consumer staples companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership.

Coca Cola Femsa has a net margin of 8.05% compared to Arcadia Biosciences' net margin of -234.53%. Coca Cola Femsa's return on equity of 15.83% beat Arcadia Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Coca Cola Femsa8.05% 15.83% 7.32%
Arcadia Biosciences -234.53%-183.50%-91.25%

Coca Cola Femsa currently has a consensus target price of $118.83, indicating a potential upside of 5.96%. Given Coca Cola Femsa's stronger consensus rating and higher probable upside, research analysts clearly believe Coca Cola Femsa is more favorable than Arcadia Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Coca Cola Femsa
0 Sell rating(s)
5 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.44
Arcadia Biosciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Coca Cola Femsa has higher revenue and earnings than Arcadia Biosciences. Arcadia Biosciences is trading at a lower price-to-earnings ratio than Coca Cola Femsa, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Coca Cola Femsa$15.22B12.39$1.32B$6.3417.69
Arcadia Biosciences$4.86M0.23-$2.34M-$4.56N/A

Coca Cola Femsa has a beta of 0.52, indicating that its share price is 48% less volatile than the broader market. Comparatively, Arcadia Biosciences has a beta of 0.56, indicating that its share price is 44% less volatile than the broader market.

In the previous week, Coca Cola Femsa had 10 more articles in the media than Arcadia Biosciences. MarketBeat recorded 10 mentions for Coca Cola Femsa and 0 mentions for Arcadia Biosciences. Coca Cola Femsa's average media sentiment score of 1.60 beat Arcadia Biosciences' score of 0.00 indicating that Coca Cola Femsa is being referred to more favorably in the media.

Company Overall Sentiment
Coca Cola Femsa Very Positive
Arcadia Biosciences Neutral

17.7% of Arcadia Biosciences shares are owned by institutional investors. 1.0% of Coca Cola Femsa shares are owned by company insiders. Comparatively, 4.5% of Arcadia Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Coca Cola Femsa beats Arcadia Biosciences on 13 of the 16 factors compared between the two stocks.

How does Arcadia Biosciences compare to Monster Beverage?

Arcadia Biosciences (NASDAQ:RKDA) and Monster Beverage (NASDAQ:MNST) are both consumer staples companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, dividends, institutional ownership, profitability, analyst recommendations and media sentiment.

In the previous week, Monster Beverage had 4 more articles in the media than Arcadia Biosciences. MarketBeat recorded 4 mentions for Monster Beverage and 0 mentions for Arcadia Biosciences. Monster Beverage's average media sentiment score of 0.73 beat Arcadia Biosciences' score of 0.00 indicating that Monster Beverage is being referred to more favorably in the news media.

Company Overall Sentiment
Arcadia Biosciences Neutral
Monster Beverage Positive

Monster Beverage has a consensus price target of $50.33, suggesting a potential upside of 5.30%. Given Monster Beverage's stronger consensus rating and higher probable upside, analysts clearly believe Monster Beverage is more favorable than Arcadia Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arcadia Biosciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Monster Beverage
0 Sell rating(s)
9 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.59

Arcadia Biosciences has a beta of 0.56, meaning that its share price is 44% less volatile than the broader market. Comparatively, Monster Beverage has a beta of 0.53, meaning that its share price is 47% less volatile than the broader market.

17.7% of Arcadia Biosciences shares are held by institutional investors. Comparatively, 72.4% of Monster Beverage shares are held by institutional investors. 4.5% of Arcadia Biosciences shares are held by company insiders. Comparatively, 8.1% of Monster Beverage shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Monster Beverage has a net margin of 23.08% compared to Arcadia Biosciences' net margin of -234.53%. Monster Beverage's return on equity of 26.02% beat Arcadia Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Arcadia Biosciences-234.53% -183.50% -91.25%
Monster Beverage 23.08%26.02%21.21%

Monster Beverage has higher revenue and earnings than Arcadia Biosciences. Arcadia Biosciences is trading at a lower price-to-earnings ratio than Monster Beverage, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arcadia Biosciences$4.86M0.23-$2.34M-$4.56N/A
Monster Beverage$8.29B11.29$1.91B$1.0844.25

Summary

Monster Beverage beats Arcadia Biosciences on 15 of the 16 factors compared between the two stocks.

How does Arcadia Biosciences compare to Coca-Cola Europacific Partners?

Arcadia Biosciences (NASDAQ:RKDA) and Coca-Cola Europacific Partners (NASDAQ:CCEP) are both consumer staples companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Coca-Cola Europacific Partners has a net margin of 0.00% compared to Arcadia Biosciences' net margin of -234.53%. Coca-Cola Europacific Partners' return on equity of 0.00% beat Arcadia Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Arcadia Biosciences-234.53% -183.50% -91.25%
Coca-Cola Europacific Partners N/A N/A N/A

17.7% of Arcadia Biosciences shares are owned by institutional investors. Comparatively, 31.4% of Coca-Cola Europacific Partners shares are owned by institutional investors. 4.5% of Arcadia Biosciences shares are owned by company insiders. Comparatively, 3.0% of Coca-Cola Europacific Partners shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Coca-Cola Europacific Partners has higher revenue and earnings than Arcadia Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arcadia Biosciences$4.86M0.23-$2.34M-$4.56N/A
Coca-Cola Europacific Partners$23.64B2.11$2.20BN/AN/A

In the previous week, Coca-Cola Europacific Partners had 2 more articles in the media than Arcadia Biosciences. MarketBeat recorded 2 mentions for Coca-Cola Europacific Partners and 0 mentions for Arcadia Biosciences. Coca-Cola Europacific Partners' average media sentiment score of 0.45 beat Arcadia Biosciences' score of 0.00 indicating that Coca-Cola Europacific Partners is being referred to more favorably in the news media.

Company Overall Sentiment
Arcadia Biosciences Neutral
Coca-Cola Europacific Partners Neutral

Coca-Cola Europacific Partners has a consensus price target of $108.56, indicating a potential upside of 0.51%. Given Coca-Cola Europacific Partners' stronger consensus rating and higher probable upside, analysts clearly believe Coca-Cola Europacific Partners is more favorable than Arcadia Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arcadia Biosciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Coca-Cola Europacific Partners
0 Sell rating(s)
4 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.64

Arcadia Biosciences has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market. Comparatively, Coca-Cola Europacific Partners has a beta of 0.51, indicating that its stock price is 49% less volatile than the broader market.

Summary

Coca-Cola Europacific Partners beats Arcadia Biosciences on 12 of the 14 factors compared between the two stocks.

Get Arcadia Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for RKDA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RKDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RKDA vs. The Competition

MetricArcadia BiosciencesBeverages IndustryConsumer Staples SectorNASDAQ Exchange
Market Cap$1.10M$23.19B$15.97B$12.83B
Dividend YieldN/A2.62%3.21%10.78%
P/E Ratio-0.1017.6913.5824.21
Price / Sales0.2331.09262,949.3194.86
Price / Cash0.3518.0456.1936.90
Price / Book0.194.064.986.42
Net Income-$2.34M$911.45M$836.78M$348.89M
7 Day Performance-26.74%2.04%0.26%0.08%
1 Month Performance-26.43%1.93%2.22%3.88%
1 Year Performance-88.81%-7.12%13.47%16.98%

Arcadia Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RKDA
Arcadia Biosciences
0.7157 of 5 stars
$0.46
-1.0%
N/A-88.8%$1.10M$4.86MN/A60
KO
CocaCola
4.5352 of 5 stars
$90.38
+1.8%
$95.76
+6.0%
+29.7%$388.88B$47.94B27.1465,900
PEP
PepsiCo
4.4696 of 5 stars
$142.58
+1.7%
$157.90
+10.7%
-4.1%$194.61B$93.93B18.69306,000
KOF
Coca Cola Femsa
3.818 of 5 stars
$113.23
+3.3%
$118.83
+4.9%
+28.6%$190.30B$296.20B17.86108,840
MNST
Monster Beverage
3.158 of 5 stars
$47.43
+0.1%
$50.33
+6.1%
+52.1%$92.92B$8.29B43.926,891

Related Companies and Tools


This page (NASDAQ:RKDA) was last updated on 8/23/2026 by MarketBeat.com Staff.
From Our Partners